Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.

This narrative review surveys the pharmacology and clinical development of long-acting amylin analogues, with cagrilintide and CagriSema as central examples alongside newer agents. It notes that gastrointestinal side effects are common during initiation but mostly resolve with continued use. As an expert overview it provides strong context on tracked peptides, though it synthesizes rather than generates primary data.